基于腋窝超声和MRI预测早期乳腺癌豁免腋窝手术的模型
本研究回顾性分析中国三个癌症中心8114例cT1-T2N0浸润性乳腺癌患者,评估术前腋窝超声和/或MRI预测前哨淋巴结转移的价值并构建预测模型。模型在训练集和验证集的AUC分别为0.775和0.759,可辅助筛选可安全豁免腋窝手术的低危患者,但豁免手术可能导致17.4%符合CDK4/6抑制剂治疗条件的患者淋巴结转移被遗漏。
要点
- 术前腋窝US和MRI阴性者前哨淋巴结转移率仍达16.39%,不能仅凭阴性影像完全排除转移。
- 整合影像与临床病理特征的列线图模型(AUC 0.759-0.775)有助于个体化筛选可豁免腋窝手术者。
- 豁免腋窝手术需权衡辅助治疗决策风险,符合CDK4/6抑制剂条件者遗漏转移比例达17.4%。
关键影像表现/征象
- 前哨淋巴结转移见于2545例(31.37%),临床T2期、脉管侵犯、Ki-67≥20%、ER+/HER2-亚型及超声或MRI阳性发现为独立预测因素(p<0.001)。
- 2282例超声和MRI均阴性的患者中,前哨淋巴结转移率为16.39%。
诊断标准与关键数值
- 预测模型在训练集AUC为0.775(95%CI:0.750-0.801),验证集AUC为0.759(95%CI:0.740-0.778)。
- 豁免腋窝手术将遗漏17.4%符合CDK4/6抑制剂治疗条件患者的淋巴结转移。
临床应用与阅片要点
- 术前应规范行腋窝超声和/或MRI评估淋巴结状态,并将影像阳性发现与临床病理特征(T2期、脉管侵犯、Ki-67≥20%、ER+/HER2-亚型)结合进行风险分层。
- 超声和MRI均阴性仍需警惕约16%的前哨淋巴结转移风险,不可仅凭阴性影像完全豁免腋窝分期。
- 对拟豁免腋窝手术者,应评估辅助全身治疗和放疗决策是否因淋巴结状态未知而受影响,尤其注意符合CDK4/6抑制剂条件者遗漏转移的风险。
局限性
- 回顾性研究设计。
- 原文未报告影像判读的一致性及设备参数细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Sentinel lymph node (SLN) biopsy remains the standard for axillary staging in early-stage breast cancer, though ongoing clinical investigations are exploring the omission of axillary procedures in specific subgroups. This study assessed whether axillary ultrasonography (US) and MRI can predict SLN involvement and developed a predictive tool to identify patients who may safely forgo axillary surgery.
MATERIALS AND METHODS: We retrospectively analyzed 8114 patients with cT1-T2N0 invasive breast cancer across three cancer centers in China. All patients underwent preoperative axillary US and/or MRI. Multivariate logistic regression identified independent predictors of SLN metastases, which were used to construct a predictive model. The model was validated using a 70:30 training-validation split and visualized through a nomogram. Subgroup analyses evaluated the risk of SLN involvement among patients with negative imaging findings.
RESULTS: SLN metastases were observed in 2545 patients (31.37%), with clinical T2 stage, lymphovascular invasion, Ki-67 ≥ 20%, ER + /HER2- subtype, and positive findings on US or MRI independently associated with SLN involvement (p < 0.001). Among 2282 patients with negative US and MRI findings, the SLN metastasis rate was 16.39%. The multivariable predictive model integrating imaging findings with clinicopathologic variables demonstrated good performance, with an AUC of 0.775 (95% CI: 0.750-0.801) in the training set and 0.759 (95% CI: 0.740-0.778) in the validation set. Notably, omission of axillary surgery would miss nodal metastases in 17.4% of patients eligible for CDK4/6 inhibitors.
CONCLUSION: Preoperative US and MRI are valuable for identifying low-risk patients. The prediction model may help select early-stage breast cancer patients for whom axillary surgery can be safely omitted while minimizing undertreatment risks for adjuvant therapies.
KEY POINTS: Question Can preoperative axillary ultrasound and MRI reliably stratify lymph node metastasis risk in patients with early-stage breast cancer? Findings A multivariate nomogram developed from 8,114 patients showed consistent predictive accuracy for axillary metastasis (AUC: 0.775 in training; 0.759 in validation cohort). Clinical relevance This model supports individualized axillary management by identifying patients who may safely avoid axillary surgery while preserving accurate nodal risk stratification for adjuvant systemic therapy and radiotherapy decision-making.
引用
- Xie H, Wang X, Guo W, et al. Prediction model to prevent axillary surgery using axillary US and MRI in early breast cancer. Eur Radiol. 2026. PMID: 41927980. doi:10.1007/s00330-026-12494-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。